Extensive Small Cell Lung Cancer Treatment Using An Investigational Drug Plus Chemotherapy In Chemotherapy-Naive Adults

Inclusion Criteria: * Written informed consent (patient's written understanding of and agreement to participate in this study). * Patients with confirmed extensive small cell lung cancer (SCLC). * No prior chemotherapy within 5 years of the diagnosis of SCLC. * Presence of either measurable or non-measurable SCLC by X-ray or physical examination. * At least 3 weeks since last major surgery (a lesser period is acceptable if decided to be in the best interest of the patient). * At least 24 hours since prior radiotherapy. Patients who have received radiotherapy must have recovered from any reversible side effects, such as nausea and vomiting. * Laboratory criteria: Patients must have adequate bone marrow reserve and adequate kidney and liver function. Exclusion Criteria: * Symptoms of spreading of the disease to the brain that requires treatment with drugs called steroids. * Any active infection. * Severe medical problems other than the diagnosis of SCLC, that would limit the ability of the patient to follow study guidelines or that would expose the patient to extreme risk. * Ongoing or planned chemotherapy, immunotherapy, radiotherapy, or investigational therapy for the treatment of SCLC. * Use of an investigational drug within 30 days before the first dose of study medication. * Women who are pregnant or lactating. * Patients of child-bearing potential who refuse to practice an adequate form of birth control. * Patients with clinical evidence of any stomach or intestinal (GI) condition. * Patients requiring treatment with the drug cyclosporin A.